Granules’s 1QFY27 EBITDA/PAT were ahead of our estimates (by 7%/11%), primarily on the back of a beat in gross margin. The gross margin (65.6%) beat was aided by a favorable mix, while the quarter’s EBITDA margin outperformance has also come in the face of elevated R&D spend.